GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Pharmacokinetics of Zanamivir After Single and Repeated Dose Infusion Administration in Healthy Chinese Adults

Phase 1

Completed

Conditions: Influenza, Human

Interventions: Drug: Zanamivir

First Posted Date: 2015-03-03

Last Posted Date: 2017-05-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 24

Registration Number: NCT02377401

Locations: 🇨🇳
GSK Investigational Site, Shanghai, China

A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor

Phase 3

Terminated

Conditions: Obstetric Labour, Premature

Interventions: Drug: Retosiban IV infusion
Drug: Placebo IV infusion

First Posted Date: 2015-03-03

Last Posted Date: 2020-07-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 25

Registration Number: NCT02377466

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Mepolizumab

First Posted Date: 2015-03-03

Last Posted Date: 2019-12-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36

Registration Number: NCT02377427

Locations: 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom

A Surveillance Study of Diseases Specified as Adverse Events of Special Interest, of Other Adverse Events Leading to Hospitalisation or Death, and of Meningitis in Children in Africa Prior to Implementation of the RTS,S/AS01E Candidate Vaccine

Completed

Conditions: Malaria

Interventions: Procedure: Blood collection

First Posted Date: 2015-02-27

Last Posted Date: 2023-01-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36366

Registration Number: NCT02374450

Locations: 🇰🇪
GSK Investigational Site, Kisumu, Kenya

Clinical Study to Evaluate the Efficacy of Two Dentifrices for Dentine Hypersensitivity

Not Applicable

Completed

Conditions: Dentine Sensitivity

Interventions: Device: Calcium sodium phosphosilicate
Other: Sodium fluoride
Other: Sodium monofluorophosphate

First Posted Date: 2015-02-25

Last Posted Date: 2018-04-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 304

Registration Number: NCT02371616

Locations: 🇬🇧
GSK Investigational Site, Wirral, United Kingdom

Drug-drug Interaction Study of GSK1278863 With Pioglitazone, Rosuvastatin and Trimethoprim in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Anaemia

Interventions: Drug: GSK1278863 25 mg Tablet
Drug: Pioglitazone 15 mg Tablet
Drug: Trimethoprim 100 mg Tablet
Drug: Rosuvastatin 10 mg Tablet

First Posted Date: 2015-02-25

Last Posted Date: 2017-11-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 70

Registration Number: NCT02371603

Locations: 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States

Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above

Phase 3

Completed

Conditions: Influenza

Interventions: Biological: Fluarix Tetra

First Posted Date: 2015-02-23

Last Posted Date: 2017-10-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 121

Registration Number: NCT02369341

Locations: 🇧🇷
GSK Investigational Site, São Paulo, Brazil

Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma

Phase 2

Withdrawn

Conditions: Sarcoma, Soft Tissue

Interventions: Drug: Pazopanib 800 mg
Drug: Placebo

First Posted Date: 2015-02-20

Last Posted Date: 2016-10-12

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT02367651

Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women

Phase 2

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: RSV vaccine GSK3003898A (formulation 2)
Biological: RSV vaccine GSK3003895A (formulation 1)
Biological: RSV vaccine GSK3003899A (formulation 3)
Biological: Boostrix